Rogers D M, Rhodes E L, Kirkland J S
Surg Clin North Am. 1986 Apr;66(2):319-31. doi: 10.1016/s0039-6109(16)43884-3.
In situ saphenous vein bypass, using the new valve incision techniques, has shown great promise in the early clinical trials to date. This procedure allows disruption of the venous valves without removal of the vein from its bed, thus allowing preservation of the vasa vasorum and maintenance of the endothelial integrity of the veins. This has allowed an overall improvement in the patency rates of the lower extremity bypasses, particularly in the bypasses to the infrapopliteal position. Also, and perhaps most important, it has permitted the use of smaller veins, with a minimum diameter of 2 mm. This greatly increases the number of patients who can benefit from such a vein bypass since reversed vein bypasses previously have required veins to have a minimum diameter of 3.5 to 4 mm. Long-term follow-up of in situ bypasses is not yet available. However, if the encouraging preliminary results of these bypasses are substantiated on long-term follow-up, in situ saphenous vein bypass may well become recognized as the procedure of choice for lower extremity bypass.
使用新的瓣膜切开技术进行原位大隐静脉旁路移植术,在迄今为止的早期临床试验中已显示出巨大的前景。该手术允许在不移除静脉的情况下破坏静脉瓣膜,从而保留滋养血管并维持静脉内皮的完整性。这使得下肢旁路移植术的通畅率总体有所提高,特别是在腘以下部位的旁路移植术中。此外,也许最重要的是,它允许使用最小直径为2毫米的较小静脉。这大大增加了能够从这种静脉旁路移植术中受益的患者数量,因为之前的反转静脉旁路移植术要求静脉的最小直径为3.5至4毫米。目前尚未获得原位旁路移植术的长期随访结果。然而,如果这些旁路移植术令人鼓舞的初步结果在长期随访中得到证实,原位大隐静脉旁路移植术很可能会被公认为下肢旁路移植术的首选方法。